Literature DB >> 28368416

Sox2 is dispensable for primary melanoma and metastasis formation.

S M Schaefer1, C Segalada1, P F Cheng2, M Bonalli1, V Parfejevs1, M P Levesque2, R Dummer2, S K Nicolis3, L Sommer1.   

Abstract

Tumor initiation and metastasis formation in many cancers have been associated with emergence of a gene expression program normally active in embryonic or organ-specific stem cells. In particular, the stem cell transcription factor Sox2 is not only expressed in a variety of tumors, but is also required for their formation. Melanoma, the most aggressive skin tumor, derives from melanocytes that during development originate from neural crest stem cells. While neural crest stem cells do not express Sox2, expression of this transcription factor has been reported in melanoma. However, the role of Sox2 in melanoma is controversial. To study the requirement of Sox2 for melanoma formation, we therefore performed CRISPR-Cas9-mediated gene inactivation in human melanoma cells. In addition, we conditionally inactivated Sox2 in a genetically engineered mouse model, in which melanoma spontaneously develops in the context of an intact stroma and immune system. Surprisingly, in both models, loss of Sox2 did neither affect melanoma initiation, nor growth, nor metastasis formation. The lack of a tumorigenic role of Sox2 in melanoma might reflect a distinct stem cell program active in neural crest stem cells and during melanoma formation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28368416     DOI: 10.1038/onc.2017.55

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

1.  Multiple roles of Sox2, an HMG-box transcription factor in avian neural crest development.

Authors:  Yoshio Wakamatsu; Yukinori Endo; Noriko Osumi; James A Weston
Journal:  Dev Dyn       Date:  2004-01       Impact factor: 3.780

2.  Sox2-positive dermal papilla cells specify hair follicle type in mammalian epidermis.

Authors:  Ryan R Driskell; Adam Giangreco; Kim B Jensen; Klaas W Mulder; Fiona M Watt
Journal:  Development       Date:  2009-07-15       Impact factor: 6.868

3.  A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.

Authors:  Marie C Zipser; Ossia M Eichhoff; Daniel S Widmer; Natalie C Schlegel; Nicola L Schoenewolf; Darrin Stuart; Weihua Liu; Humphrey Gardner; Paul D Smith; Paolo Nuciforo; Reinhard Dummer; Keith S Hoek
Journal:  Pigment Cell Melanoma Res       Date:  2011-01-12       Impact factor: 4.693

4.  The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.

Authors:  Daniel Zingg; Julien Debbache; Simon M Schaefer; Eylul Tuncer; Sandra C Frommel; Phil Cheng; Natalia Arenas-Ramirez; Jessica Haeusel; Yudong Zhang; Mario Bonalli; Michael T McCabe; Caretha L Creasy; Mitchell P Levesque; Onur Boyman; Raffaella Santoro; Olga Shakhova; Reinhard Dummer; Lukas Sommer
Journal:  Nat Commun       Date:  2015-01-22       Impact factor: 14.919

5.  SOX2 is a dose-dependent regulator of retinal neural progenitor competence.

Authors:  Olena V Taranova; Scott T Magness; B Matthew Fagan; Yongqin Wu; Natalie Surzenko; Scott R Hutton; Larysa H Pevny
Journal:  Genes Dev       Date:  2006-05-01       Impact factor: 11.361

Review 6.  Testing the cancer stem cell hypothesis in melanoma: the clinics will tell.

Authors:  Olga Shakhova; Lukas Sommer
Journal:  Cancer Lett       Date:  2012-10-13       Impact factor: 8.679

Review 7.  Paradoxical role of SOX2 in gastric cancer.

Authors:  Estefania Carrasco-Garcia; Juliana C Santos; Idoia Garcia; Mitsue Brianti; Mikel García-Puga; José Pedrazzoli; Ander Matheu; Marcelo L Ribeiro
Journal:  Am J Cancer Res       Date:  2016-03-15       Impact factor: 6.166

8.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

9.  SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin.

Authors:  Giustina Ferone; Ji-Ying Song; Kate D Sutherland; Rajith Bhaskaran; Kim Monkhorst; Jan-Paul Lambooij; Natalie Proost; Gaetano Gargiulo; Anton Berns
Journal:  Cancer Cell       Date:  2016-10-10       Impact factor: 31.743

10.  A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation.

Authors:  Charles K Kaufman; Christian Mosimann; Zi Peng Fan; Song Yang; Andrew J Thomas; Julien Ablain; Justin L Tan; Rachel D Fogley; Ellen van Rooijen; Elliott J Hagedorn; Christie Ciarlo; Richard M White; Dominick A Matos; Ann-Christin Puller; Cristina Santoriello; Eric C Liao; Richard A Young; Leonard I Zon
Journal:  Science       Date:  2016-01-28       Impact factor: 47.728

View more
  14 in total

1.  Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.

Authors:  V Cesarini; E Guida; F Todaro; S Di Agostino; V Tassinari; S Nicolis; R Favaro; S Caporali; P M Lacal; E Botti; A Costanzo; P Rossi; E A Jannini; S Dolci
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

2.  CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma.

Authors:  Dinoop Ravindran Menon; Yuchun Luo; John J Arcaroli; Sucai Liu; Lekha Nair KrishnanKutty; Douglas G Osborne; Yang Li; Jenny Mae Samson; Stacey Bagby; Aik-Choon Tan; William A Robinson; Wells A Messersmith; Mayumi Fujita
Journal:  Cancer Res       Date:  2018-10-08       Impact factor: 12.701

3.  Classification and Grading of Melanocytic Lesions in a Mouse Model of NRAS-driven Melanomagenesis.

Authors:  Charles-Antoine Assenmacher; Sara F Santagostino; Mark A Oyama; Jean-Christophe Marine; Elise Bonvin; Enrico Radaelli
Journal:  J Histochem Cytochem       Date:  2020-12-07       Impact factor: 2.479

4.  SOX2 as a novel contributor of oxidative metabolism in melanoma cells.

Authors:  Elena Andreucci; Silvia Pietrobono; Silvia Peppicelli; Jessica Ruzzolini; Francesca Bianchini; Alessio Biagioni; Barbara Stecca; Lido Calorini
Journal:  Cell Commun Signal       Date:  2018-11-22       Impact factor: 5.712

5.  Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.

Authors:  Mariusz L Hartman; Malgorzata Sztiller-Sikorska; Anna Gajos-Michniewicz; Malgorzata Czyz
Journal:  Cells       Date:  2020-01-07       Impact factor: 6.600

Review 6.  Reemergence of neural crest stem cell-like states in melanoma during disease progression and treatment.

Authors:  Johanna Diener; Lukas Sommer
Journal:  Stem Cells Transl Med       Date:  2020-12-01       Impact factor: 6.940

Review 7.  Research Progress of Cancer Stem Cells in Uveal Melanoma.

Authors:  Yu Ning Chen; Yang Li; Wen Bin Wei
Journal:  Onco Targets Ther       Date:  2020-11-27       Impact factor: 4.147

Review 8.  Induced Pluripotency: A Powerful Tool for In Vitro Modeling.

Authors:  Romana Zahumenska; Vladimir Nosal; Marek Smolar; Terezia Okajcekova; Henrieta Skovierova; Jan Strnadel; Erika Halasova
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

Review 9.  Mitochondrial Metabolism in Melanoma.

Authors:  Christina Huang; Rakan H Radi; Jack L Arbiser
Journal:  Cells       Date:  2021-11-16       Impact factor: 6.600

10.  Genes Involved in the Transcriptional Regulation of Pluripotency Are Expressed in Malignant Tumors of the Uterine Cervix and Can Induce Tumorigenic Capacity in a Nontumorigenic Cell Line.

Authors:  Graciela Ruiz; Heriberto A Valencia-González; Delia Pérez-Montiel; Felipe Muñoz; Rodolfo Ocadiz-Delgado; Jorge Fernández-Retana; Carlos Pérez-Plasencia; Osbaldo Reséndis-Antonio; Patricio Gariglio; Alejandro García-Carrancá
Journal:  Stem Cells Int       Date:  2019-12-01       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.